State Trading Organization (STO) Medical Services recently brought together over 100 healthcare professionals to discuss critical issues related to chronic kidney disease, diabetes, and cardiac conditions.

The conference, titled “Cardio Metabolic Renal Conclave,” held at CROSSROADS Maldives on Friday, highlighted the recent US FDA approval of a medication manufactured by AstraZeneca, imported, and distributed by STO. “This medication is designed to improve glycemic control in children aged 10 years and older with type 2 diabetes, marking a crucial milestone for patients living with type 2 diabetes and extending the potential benefits to many more individuals facing high unmet needs,” the state-owned company said in a statement.

The event, focused on the importance of managing type 2 diabetes and introducing the latest globally approved medications for treating cardio, renal, and metabolic diseases related to diabetes, featured presentations by field experts including Dr. Mohamed Shiruhan, Dr. Ibrahim Shiham, and Dr. Shaneez Najmy. Through the presentations, they shared their extensive knowledge and expertise in treating chronic kidney disease, diabetes, and cardiac conditions, including heart failure.

The conference theme, “salt, water, and sugar,” underscored the comprehensive approach needed to tackle cardiovascular, metabolic, and renal health. At the event, Dr Sanjay Kalra, Chairperson of the Education Working Group of the International Society of Endocrinology (ISE), also shared his insights on glycemic control in type 2 diabetes management.

The conference was organised as part of STO’s dedication to equip healthcare professionals with the latest medical knowledge and advancements while continuing to explore innovative methods to elevate the healthcare sector in the country. “This conference is a testament to STO’s commitment to improving healthcare outcomes and supporting medical professionals in their mission to provide the best possible care for their patients,” the company said.